Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (September 2021)

43 slides from Windtree Therapeutics's investor presentation, Sep 20, 2021

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics Company Overview September 20, 2021 WINDTREE THERAPEUTICS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights GS Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) GF Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths:

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline elimina [re | Phases | phase | phase |Next nttestone | Istaroxime (Acute Heart Failure) Potential for Istaroxime Breakthrough _—_ (Early Cardiogenic Shock) designation Oral SERCA2a Activators (Chronic HF; potentially HFpEF) KL4 Surfactant —COVID 19 (COVID 19 Pilot; Pos

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones Q2 Q3 Q4 Ql Q2 Q3 Q4 Istaroxime Early Cardiogenic Shock Study Data ---~ Istaroxime Data, then Acute Heart Failure Study EOP2 Miginto (transition to Phase 3)** iret artnerin KL4 Surfactant nin COVID-19 Lung Injury Treatment / Data Timing TBO: AEROSURF AE

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2aq Activator Acute Heart Failure and

  7. Slide 7: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing Vv 6M U.S., 20M+ worldwide patients Vv #1 cause of U.S. hospitalization in patients > 65 years old; * >1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) In-patien

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need = Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g. “dry out”) with i.v. diuretics * Improve cardiac function and peripheral/organ perfusion * Achieve stable, fully compensated clinical

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart =~ = Inhibition of the sodium- Stimulation of SERCA2a activity enhances calcium reuptake resulting in ; . potassium pumpandeffectson [StarOxXime improvemen

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies —- Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients SB & © n=120 Dosing= 6 hour Phase 25 ADHF Patients 0.5, 1, 1.5 ug/kg/min Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0.5, 1.0 ue/kg/min Infusion (dyspnea plus need

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio and Stroke Volume istaroxime 0.5 pg/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 20 20 10 10 00 0 10 10 e 2.20 $20 é é 30 yy 30 a Fe’ 3, 50 50 Infusion period Infusion period * j * ‘ a e * pyvalue = 0.029 a? Paes See 10 70 Bacine

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo ———— a 9 = Systolic & Blood 3 Pressure = 2 (SBP) é Infusion period 7 erat t 3 : = 011, ** p-values $0006 geal or agro godt gaa ero gyro a po

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 pg/kg/min vs. placebo a5 * pvalue=0.014 Change in Heart Rate (bpm) Infusion period =-9= Placeto-Cohot 1 ge isteroxime0.S us/Ke/min cTnT — 0 to 24 hours o 3 6 § 2 wa wm Heart Rate istaroxime 1.0 pg/kg/min vs. placebo 9 : Infusi

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Clinically Significant Arrhythmias Clinically Significant Arrhythmias 12.0% 10.5% 10.5% 10.5% 25.0% 2o0% 200% 200% 100% - 30% 15.0% 25% 50% jo0% jo0% 100% 7 28% 28% 28% ee | a | oo oo% oo% Bas

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Cardiogenic Shock

    Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf

  18. Slide 18: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrythmias, decreasing blood pressure, renal dysfunction and

  19. Slide 19: Changes in SBP — Phase 2a and 2b Dose Groups

    Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change 0.5 pg/kg/min 1.0 g/kg/min 1.5 pg/kg/min Study/Dose Mean SBP at Baseline “112 mmHg m6 Hours m 24 H

  20. Slide 20: Istaroxime Early Cardiogenic Shock Study

    Istaroxime Early Cardiogenic Shock Study Ongoing early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure S E70 ~60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF in the EU and US 1.0 - 1.5ug/kg/min targ

  21. Slide 21: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation Istarox

  22. Slide 22: Summary: Potential to Create Value

    Summary Potential to Create Value Acute heart failure — large market with significant unmet need * Istaroxime appears to be the only drug in phase 2 or phase 3 development for AHF treatment Istaroxime — dual-mechanism therapy with positive phase 2a and 2b trial outcomes: v Improved cardiac function

  23. Slide 23: Lyo Lucinactant

    Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients

  24. Slide 24: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function

    COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses angiotensin- ACE2 is surface molecule on converting enzyme 2 alveolar Type 2 lung cells — inflated and for proper gas exchange; (ACE2) for entry into host the source of surfactant Type 2 cell damage results

  25. Slide 25: Surfactant Administration in Severe COVID-19 Lung Injury

    Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits j . = Synthetic KL4 surfactant may mitigate surfactant deficiency Be ee] and resist widespread surfactant destruction that can . occur as a result of COVID-19 = Synthetic KL4 surfactant remove

  26. Slide 26: Phase 2 Study of Lucinactant for Treatment of COVID-19

    Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS ¢ Up to 20 patients from 4-5 US sites and up to 4 sites in Latin America FF

  27. Slide 27: AEROSURF

    AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)

  28. Slide 28: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli

  29. Slide 29: AEROSURF - Potential to Impact the Clinical Course of RDS

    AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Respiratory Parameters Long-Term Outcomes Study results show evidence of potential impact on clinical course of RDS and respiratory health of preterm infan

  30. Slide 30: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach (1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: * Demonstrate that new ADS works and supplement phase 2 data * Optimize dosing with more drug and shorter repeat intervals v Transition

  31. Slide 31: Financial Summary & Capitalization as of June 30, 2021

    Financial Summary & Capitalization as of June 30, 2021 = Cash & Equivalents of ~$30.0 million re Common Equivalents Securities q as of June 30, 2021 Common Stock 26,704,456 Options (WAEP $11.30) 3,266,141 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 46,599,399 SQ winotREe @ vrewarcurie

  32. Slide 32: Strategy for Value Generation

    Strategy for Value Generation Se we WINDTREE THERAPEUTICS. G Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts (Of Transactions: * Secure focused BD transactions for deal revenue and

  33. Slide 33: Windtree Therapeutics

    Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” Se wINDTREE we

  34. Slide 34: Appendix

    Appendix

  35. Slide 35: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need = Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  36. Slide 36: Istaroxime Phase 2a (HORIZON-HF) Study

    R é = Multicenter, double blind, placebo- controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% © SBP 90-150 mmHg = N=120 (30/group) = Significant improvement in PCWP, SBP, heart rate was lower. Ist

  37. Slide 37: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events Pooled placebo (n=39) istaroxime 0.5 me/Ke/min (n=41) istaroxime 1.0 Alladverse events Adverse events leading to discontinuation Serious adverse events 2 (5.1%) Cardiac death - Cardiogenic shock z 23 (59.0%) 1 (2.6%) Cardiac failure 1 (2.6%) Renal embolism = Transi

  38. Slide 38: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur

  39. Slide 39: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID- Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicabi of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic Demons tility of Extensive St

  40. Slide 40: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  41. Slide 41: Windtree Technology Platform — AEROSURF

    Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ability to aerosolize KLa surfactant for RDS approved by the FDA Lyo

  42. Slide 42: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy Reversing surfactant deficiency hasa profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement es BPD Infection, ventilator-induced pneumonia RISKS cord damage, asthma, lung damage nCPAP Respirator

  43. Slide 43: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia wider Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out-Li

Windtree Therapeutics — Investor Presentation (September 2021) on 6ix